Document Detail


Norcantharidin preferentially induces apoptosis in human leukemic Jurkat cells without affecting viability of normal blood mononuclear cells.
MedLine Citation:
PMID:  17442474     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Norcantharidin (NCTD) is known to have anti-cancer potentials. The aim of this study was to assess the apoptosis-inducing effect of NCTD on human leukemic Jurkat cells. We found that NCTD preferentially inhibited the growth of Jurkat cells in a dose- and time-dependent manner, but not the growth of normal blood mononuclear cells (MNC). Pretreatment with agonistic (CH-11) and antagonistic (ZB4) Fas antibodies on Jurkat cells showed that NCTD-induced apoptosis might not involve Fas-FasL signaling. Flow cytometric assay of Jurkat cells treated with NCTD showed a markedly increased sub-G1 DNA phase and cell cycle arrest at S phase. Western blot analysis of NCTD-treated cells showed increased expressions of cytochrome c, active caspase-9 and -3, and cleavage of poly(ADP-ribose) polymerase (PARP), but the expressions of Bcl-2, Bax and apoptosis-inducing factor were not increased. The transcription factor STAT1 was translocated from cytosol to nucleus. Pancaspase inhibitor z-VAD-FMK not only limited the level of sub-G1 phase, but also prevented the degradation of PARP in NCTD-treated cells. The NCTD-induced cell cycle arrest and apoptosis were mediated through the regulation of ataxia-telangiectasia mutated (ATM), rather than P63 protein. The conditioned medium produced from human MNC (NCTD-MNC-CM) increased the percentage of apoptotic cells and the expression of PARP cleavage in Jurkat cells. Protein array assay of NCTD-MNC-CM showed 32.4- and 6.2-folds increases in TNF-alpha and GM-CSF, respectively, and the expression of MCP-1, GRO, RANTES and IL-10 was decreased. We conclude that NCTD can induce apoptosis in human leukemic Jurkat cells via a caspase-dependent pathway without affecting the viability of normal MNC, and that the apoptosis-inducing effect of NCTD can also be achieved by soluble cytokines produced from peripheral MNC.
Authors:
Hui-Fen Liao; Shu-Li Su; Yu-Jen Chen; Chin-Hung Chou; Cheng-Deng Kuo
Related Documents :
15314284 - Rip kinase is involved in arsenic-induced apoptosis in multiple myeloma cells.
14678744 - Lovastatin-induced cardiac toxicity involves both oncotic and apoptotic cell death with...
19909374 - Adapter and enzymatic functions of proteases in t-cell activation.
15316934 - Caspase-3 inhibits the growth of breast cancer cells independent of protease activity.
19040574 - The metalloproteinase adam-12 regulates bronchial epithelial cell proliferation and apo...
14715444 - Parkinson's disease and inflammatory changes.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2007-03-12
Journal Detail:
Title:  Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association     Volume:  45     ISSN:  0278-6915     ISO Abbreviation:  Food Chem. Toxicol.     Publication Date:  2007 Sep 
Date Detail:
Created Date:  2007-08-01     Completed Date:  2007-10-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8207483     Medline TA:  Food Chem Toxicol     Country:  England    
Other Details:
Languages:  eng     Pagination:  1678-87     Citation Subset:  IM    
Affiliation:
Laboratory of Biophysics, Department of Research and Education, Taipei Veterans General Hospital, Taipei 112, Taiwan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents / pharmacology*
Apoptosis / drug effects*
Bicyclo Compounds, Heterocyclic / pharmacology*
Blotting, Western
Caspases / metabolism
Cell Proliferation
Cell Survival / drug effects
Cytokines / biosynthesis
DNA / metabolism
Dose-Response Relationship, Drug
Flow Cytometry
Humans
Jurkat Cells / drug effects*
Leukocytes, Mononuclear / cytology,  drug effects*,  metabolism
MAP Kinase Signaling System / drug effects
S Phase / drug effects*
Time Factors
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Bicyclo Compounds, Heterocyclic; 0/Cytokines; 5442-12-6/norcantharidin; 9007-49-2/DNA; EC 3.4.22.-/Caspases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Buprenorphine substitution treatment in France: drug users' views of the doctor-user relationship.
Next Document:  Pyrogallol, ROS generator inhibits As4.1 juxtaglomerular cells via cell cycle arrest of G2 phase and...